Uplizna (inebilizumab-cdon) was found effective both at reducing attacks and lessening disability in people with neuromyelitis optica spectrum disorder…
Articles by Patricia Inacio, PhD
About a third of adults with neuromyelitis optica spectrum disorder (NMOSD) have cognitive impairments, affecting mostly visual…
The use of immunomodulatory therapy based on type 1 interferons (IFNs) may trigger neuromyelitis optica spectrum disorder…
Constipation may be linked with pain due to nerve cell damage in people diagnosed with neuromyelitis optica spectrum disorder (NMOSD) and…
People with neuromyelitis optica spectrum disorder (NMOSD), but lacking anti-AQP4 and anti-MOG antibodies, show no signs of damage to…
InnoCare Pharma will soon launch a Phase 2 clinical trial in China to test orelabrutinib, its oral investigational Bruton…
Merck KGaA will continue to advance CRD1 for the treatment of neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis…
A committee of the European Medicines Agency has recommended approving Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum…
Treatment with Horizon Therapeutics’ Uplizna (inebilizumab-cdon) was found safe and effective at reducing the frequency of attacks in African-American…
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less…